Israel has reopened the Rafah border crossing between Gaza and Egypt for limited pedestrian movement, a move long demanded by aid agencies. However, the crucial flow of humanitarian supplies remains restricted, and the reopening follows deadly violence in the area.
A Russian drone strike targeted a bus carrying coal miners in Ukraine's Dnipropetrovsk region on Sunday, killing at least 12 workers and wounding eight others, in what Ukrainian officials describe as a deliberate attack on civilian infrastructure.
Venezuela has released more than 30 individuals classified as political prisoners, according to a leading rights organization. The move follows the government's announcement of a proposed amnesty law and comes amid mounting international pressure and domestic calls for faster action.
Mueller Industries' stock has soared roughly 700% over the past five years, leaving investors to question if the capital goods standout still holds value. With shares trading near $136, we analyze its valuation through cash flow models and peer comparisons to gauge the path ahead.
BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.
Allegion (NYSE: ALLE) is accelerating its strategic shift toward integrated smart security platforms, emphasizing digital credentials, connected locks, and cloud-based access control to meet growing demand from commercial and institutional clients.
As the ASX braces for a turbulent week amid rate hike fears, investors are scouring the market for resilient opportunities. We delve into three penny stocks—spanning energy, retail, and healthcare—that combine financial stability with distinct growth narratives for the discerning investor.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
Facing an eighth consecutive month of declining deliveries, Li Auto is restructuring its R&D and betting on its upgraded L9 model. Amid a falling share price, analysts debate whether the current valuation presents a buying opportunity or reflects deeper challenges.
Tesla's stock is navigating turbulent waters, with a recent one-day surge contrasting sharply against a weaker quarterly performance. As the EV pioneer's share price hovers above some analyst targets, investors are left weighing its ambitious robotaxi and AI-driven future against more conservative valuation models.
Shares of Perspective Therapeutics (CATX) have rallied sharply following encouraging interim results from its lead cancer therapy trial and a strategic business update. While the data fuels optimism, a deep dive into the numbers reveals a stark disconnect between its current market price and analyst targets, highlighting both opportunity and significant risk.
Christie Oster, a recently honored middle school educator in Lafayette Parish, faces serious felony charges following allegations of an inappropriate relationship with a former student, casting a shadow over her celebrated career.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Driven by a global wave of semiconductor investment, Applied Materials (AMAT) has received a series of analyst upgrades. Mizuho and Deutsche Bank are among those highlighting the company's strategic position to benefit from expansive fab construction in the U.S., Taiwan, and Japan, and its key role in next-generation chip technologies.
The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
Faced with the realities of modern warfare in Ukraine, NATO is fast-tracking innovation, creating an unprecedented opportunity for agile tech founders to access a once-closed defense market.
Amid a steep 60% annual share price decline, investment firm Chicago Capital has significantly reduced its position in PROCEPT BioRobotics, a developer of robotic systems for urological surgery, signaling a portfolio risk reassessment.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
